← All research projects

NEOTRAPSCAL

Data analysis

NEOTRAPSCAL

NEOTRAPSCAL is a prospective, multicenter observational study evaluating the real-world effectiveness and safety of fixed-dose subcutaneous trastuzumab–pertuzumab (Phesgo) combined with neoadjuvant chemotherapy in Algerian women with non-metastatic HER2-positive breast cancer. The study targets 70 patients, with pathological complete response as its primary endpoint.

Evaluation of the Efficacy of Subcutaneous Trastuzumab-Pertuzumab Combination in Neoadjuvant Treatment of Non-Metastatic HER2-Positive Breast Cancer in Algerian Women

My role: Contribution to the scientific and methodological development of the study, multicenter research coordination, clinical data management, statistical analysis, and scientific dissemination of research findings. Start: 1 Mar 2025 End: 31 Dec 2025

Overview

Overview

Dual HER2 blockade with trastuzumab and pertuzumab is an established component of neoadjuvant treatment for HER2-positive breast cancer. The fixed-dose subcutaneous formulation provides an alternative administration route, with potential benefits for treatment delivery, healthcare organization, and patient experience.
NEOTRAPSCAL was developed to evaluate the effectiveness and tolerability of this therapeutic approach in routine clinical practice in Algeria.
The study follows women with non-metastatic HER2-positive breast cancer receiving subcutaneous trastuzumab–pertuzumab in combination with standard neoadjuvant chemotherapy before surgery.
The primary focus is pathological complete response, complemented by assessments of breast-conserving surgery, treatment-related adverse events, patient satisfaction, and potential predictors of therapeutic response.
By generating locally relevant real-world evidence, NEOTRAPSCAL aims to improve understanding of neoadjuvant anti-HER2 treatment outcomes and support the optimization of breast cancer care in Algerian oncology centers.

Objectives

Objectives

  • Evaluate pathological complete response following neoadjuvant subcutaneous trastuzumab–pertuzumab combined with chemotherapy.
  • Determine the proportion of patients undergoing breast-conserving surgery.
  • Assess the frequency and severity of treatment-related adverse events.
  • Evaluate patient satisfaction with subcutaneous treatment administration.
  • Investigate clinical, pathological, and biological factors associated with pathological complete response.
  • Generate real-world evidence regarding the effectiveness and safety of subcutaneous dual HER2 blockade in Algerian clinical practice.

Study design & methods

Study design & methods

Prospective, multicenter, single-cohort observational study. Patients receive fixed-dose subcutaneous trastuzumab–pertuzumab in combination with standard neoadjuvant chemotherapy according to routine clinical practice.

Eligible patients receive subcutaneous trastuzumab–pertuzumab combined with standard neoadjuvant chemotherapy, generally administered over approximately 18 weeks before definitive surgery.
Baseline assessments include demographic characteristics, clinical presentation, tumor stage, histopathological findings, and relevant biological markers.
Treatment response and adverse events are documented throughout neoadjuvant therapy. Following surgery, pathological complete response is determined through histopathological examination of breast and axillary specimens.
The primary endpoint is defined as the absence of residual invasive carcinoma in the breast and axillary lymph nodes (ypT0/Tis ypN0).
Secondary analyses assess breast-conserving surgery rates, treatment safety, patient satisfaction, and associations between baseline characteristics and pathological response.

Study population

Study population

Adult women aged 19 years or older with histologically confirmed HER2-positive, non-metastatic breast cancer who are candidates for neoadjuvant treatment.
Key eligibility criteria include ECOG performance status ≤ 2, left ventricular ejection fraction ≥ 50%, and written informed consent.
Patients with distant metastases, previous anti-HER2 treatment, or contraindications to trastuzumab or pertuzumab are excluded.
Target sample: 70 patients.

Key project data

Key project data

StatusData analysis
Study designProspective, multicenter, single-cohort observational study. Patients receive fixed-dose subcutaneous trastuzumab–pertuzumab in combination with standard neoadjuvant chemotherapy according to routine clinical practice.
SettingThe study is designed to involve three oncology centers in Algeria: Anti-Cancer Center of Blida. Public Hospital of Aïn Defla. Public Hospital of Médéa. Treatment is delivered within routine clinical care pathways, with prospective documentation of therapeutic outcomes.
Disease areaNon-Metastatic HER2-Positive Breast Cancer
Research domainMedical Oncology; Targeted Therapies; Neoadjuvant Treatment; Observational Clinical Research; Real-World Evidence.
Geographic scopeMulticenter — Algeria (Blida, Aïn Defla, and Médéa)
Study phaseNot applicable — Observational study
Centres3
Funding: None

Endpoints

Endpoints

  • Primary endpoint: Pathological complete response rate (ypT0/Tis ypN0), assessed at surgery approximately 18–24 weeks after treatment initiation.
  • Secondary endpoint: Breast-conserving surgery rate following neoadjuvant treatment.
  • Secondary endpoint: Incidence and severity of treatment-related adverse events, assessed using CTCAE criteria.
  • Secondary endpoint: Patient satisfaction with subcutaneous treatment administration.
  • Exploratory endpoint: Clinical, pathological, and biological predictors of pathological complete response.

Key results

Key results

  • No validated final effectiveness or safety results are currently available for public reporting.
  • Clinical outcomes will be reported following completion of data analysis and scientific validation.

Additional information

Additional information

NEOTRAPSCAL contributes to the development of observational clinical research focused on targeted breast cancer therapies in Algeria.
The project provides an opportunity to investigate real-world neoadjuvant treatment outcomes, explore predictors of pathological response, and assess patient experience with subcutaneous anti-HER2 therapy.
The findings may inform future prospective research and contribute to evidence-based optimization of breast cancer care pathways in Algerian oncology institutions.